Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study
Publication date: November 2026 Source: Clinical Therapeutics, Volume 48, Issue 11 Author(s): Elizabeth Roof, Theresa V. Strong, Diane E.J. Stafford, Deepan Singh, Sani M. Roy, Dilesh Doshi, Yang Zhang, Alana Salvucci, James M. Youakim, Shawn E. McCandless, COMPASS PWS Investigators
Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study. // Clinical Therapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S0149291826002341?dgcid=rss_sd_all
Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study. Clinical Therapeutics. https://www.sciencedirect.com/science/article/pii/S0149291826002341?dgcid=rss_sd_all
“Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study.” Clinical Therapeutics.
@article{article41658,
title = {Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study},
journal = {Clinical Therapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S0149291826002341?dgcid=rss_sd_all}
}